Heart Health After 50, by the Evidence: Blood Pressure, Cholesterol, and What the Trials Show

After 50, the arithmetic of heart disease changes. The plumbing has had more decades to accumulate wear, and the risk of a heart attack or stroke climbs steeply with each passing year. That is the bad news and, oddly, the reason prevention matters more than ever: when baseline risk is high, a treatment that removes even a modest slice of it prevents a real event for more people. This is the pillar of a four-part series on cardiovascular prevention after 50. It walks through the levers with the strongest randomized evidence, blood pressure, cholesterol and statins, diet and exercise, and aspirin, and points to the deeper spoke articles on each. Throughout, we lean on the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease (Arnett et al., Circulation, 2019) and on the landmark trials behind it.

Why age changes the math: absolute vs relative risk

The most useful idea in prevention is also the most misunderstood. Relative risk reduction describes how much a treatment shrinks your risk in percentage terms. Absolute risk reduction describes how many actual events it prevents, per hundred or per thousand people treated. A drug can cut relative risk by 25 percent and still prevent very few events if the underlying risk is tiny.

Age is what turns that abstraction into something concrete. A 40-year-old with a 3 percent ten-year risk of a heart attack or stroke and a 65-year-old with a 20 percent risk might get the same relative benefit from the same pill. But 25 percent off 3 percent removes far less than 25 percent off 20 percent. The older person gains more in absolute terms from the identical treatment.

This is why the 2019 ACC/AHA guideline frames prevention around estimated ten-year risk rather than any single number in isolation (Arnett et al., Circulation, 2019). It is also why a related metric, the number needed to treat (NNT), the count of people who must take a treatment for a set time to prevent one event, tends to look better as baseline risk rises. Where trials report an NNT, we cite it, because it translates a percentage into something you can picture.

Blood pressure: among the strongest evidence

Of the four levers, blood pressure control rests on some of the most consistent randomized data, and the SPRINT trial is the reason. SPRINT enrolled more than 9,000 adults aged 50 and older at high cardiovascular risk, excluding people with diabetes or prior stroke, and randomly assigned them to a more intensive systolic target (below 120 mm Hg) or a standard one (below 140 mm Hg) (SPRINT Research Group, NEJM, 2015).

The intensive group had roughly a 25 percent lower rate of the primary composite of major cardiovascular events and about a 27 percent lower rate of death from any cause. The benefit was large enough that the trial was stopped early. In absolute terms, the numbers needed to treat over the study were in the neighborhood of 60 to prevent one primary-outcome event and around 90 to prevent one death, a reminder that even a strong relative effect still means most treated people would not have had an event either way.

The intensive strategy was not free of downsides. SPRINT recorded more of certain adverse events, including low blood pressure, fainting, and some kidney measures, in the intensive arm. That trade-off, and how blood pressure is measured in the first place, is the subject of the blood pressure spoke.

Cholesterol and statins: benefit tracks LDL lowering

The evidence on cholesterol is unusually clean for a reason: the effect scales with the dose of LDL reduction. The Cholesterol Treatment Trialists’ Collaboration pooled individual data from many statin trials and found that each 1 mmol/L (about 39 mg/dL) reduction in LDL cholesterol was associated with roughly a 22 percent lower rate of major vascular events per year (Cholesterol Treatment Trialists’ Collaboration, Lancet, 2010). The relationship held across a wide range of starting cholesterol levels and patient types.

That proportionality is what makes statins a mainstay of the ACC/AHA prevention framework (Arnett et al., Circulation, 2019). The same logic about absolute risk applies here. The relative benefit is fairly constant, so the people who gain the most in absolute terms are those whose baseline risk is highest, which after 50 is a growing share of the population.

Statins carry their own questions, from muscle symptoms to the sometimes-overstated diabetes signal, and newer non-statin options complicate the picture. The statins spoke takes those on directly.

Diet and exercise: real randomized support, modest single-lever effects

Lifestyle advice is often delivered as a vague command to eat better and move more. Some of it, though, has been tested in randomized trials. The DASH trial randomly assigned adults to a control diet, a fruit-and-vegetable diet, or a combination diet rich in fruits, vegetables, and low-fat dairy and lower in saturated fat (Appel et al., NEJM, 1997).

The combination (DASH) diet lowered blood pressure within weeks, by about 5.5 mm Hg systolic and 3.0 mm Hg diastolic on average, and by more in participants who already had high blood pressure. That is a meaningful shift for a change in eating alone, achieved without weight loss or sodium restriction as the primary driver in that particular trial.

Exercise evidence is more varied in design, but physical activity is woven through the ACC/AHA guideline as a foundation of prevention (Arnett et al., Circulation, 2019). The candid framing is that any single lifestyle lever tends to produce a modest effect on its own, and the strongest trial data sit with specific, structured patterns like DASH rather than with generic exhortations. The diet and exercise spoke sorts the tested from the merely popular.

Aspirin: a role that has shrunk

Aspirin is the clearest example in this series of evidence moving against a once-standard practice. For decades, a daily low-dose aspirin was widely recommended to prevent a first heart attack or stroke. Newer trials found that in people without established cardiovascular disease, the reduction in clotting events was offset by a rise in bleeding, including gastrointestinal and, less often, brain bleeds.

The US Preventive Services Task Force revised its position accordingly. Its 2022 statement concludes that starting aspirin for primary prevention in adults 60 and older should not be initiated, and that for adults 40 to 59 with elevated cardiovascular risk it is a small net benefit best decided individually (USPSTF, JAMA, 2022). The bleeding risk that tips the balance rises with age, which is exactly the group once most likely to be told to take it.

One caution worth stating plainly: this concerns starting aspirin for primary prevention. People already taking it, or taking it after a diagnosed cardiovascular event (secondary prevention), are a different situation entirely. The aspirin spoke unpacks where the line falls.

How the four levers fit together

No single trial captures cardiovascular prevention, and no single lever carries it. The 2019 ACC/AHA guideline reads as a synthesis: estimate a person’s overall risk, then apply the interventions whose randomized evidence is strongest, weighted toward those with the most to gain (Arnett et al., Circulation, 2019).

The pattern across the evidence is consistent. Blood pressure and cholesterol have large, replicated trial effects. Diet and exercise have solid but more modest single-lever effects and work best in combination and over time. Aspirin has moved from routine to selective. The common thread is that benefit is largest where baseline risk is highest, which, after 50, is the situation more and more readers find themselves in. The spokes go deeper on each; this page is the map.

This article reports what randomized trials and current guidelines have found. It is evidence reporting, not medical advice. It does not tell you what to take, what number to aim for, or what to do. Trials describe averages across thousands of people; you are one person, with your own history, other conditions, and medications that can change the calculus entirely. Decisions about blood pressure, cholesterol, aspirin, and lifestyle belong with you and your own clinician, who can weigh your specific risk against the evidence summarized here.

Common questions

Is high blood pressure or high cholesterol more important to address after 50?

The trials do not pit them against each other, and the ACC/AHA guideline treats both as major, independent levers (Arnett et al., Circulation, 2019). Blood pressure control (SPRINT Research Group, NEJM, 2015) and LDL lowering (Cholesterol Treatment Trialists’ Collaboration, Lancet, 2010) each produced large risk reductions in their own trials. Which matters more for a given person depends on that person’s individual risk profile, a judgment for their clinician.

Why did the aspirin advice change?

Newer randomized trials in people without established heart disease found that aspirin’s reduction in clotting events was largely offset by an increase in bleeding, and that bleeding risk rises with age. The USPSTF’s 2022 statement reflects that shift, advising against starting aspirin for primary prevention at 60 and older and calling it an individual decision at 40 to 59 (USPSTF, JAMA, 2022). This is about starting aspirin to prevent a first event, not about people already on it after a diagnosis.

What is the difference between relative and absolute risk, and why should I care?

Relative risk reduction is the percentage a treatment shaves off your risk. Absolute risk reduction is how many real events it prevents per group of people treated. A 25 percent relative cut sounds identical whether your starting risk is 3 percent or 20 percent, but it prevents far more events in the higher-risk case. Because risk climbs with age, absolute benefit generally grows after 50 even when the relative effect stays the same.

Can diet and exercise replace medication?

The evidence does not support framing it that way. The DASH trial showed a real blood-pressure drop from diet alone (Appel et al., NEJM, 1997), and activity is foundational in the guideline. But single lifestyle levers tend to produce modest effects, and the drug trials measured benefits on top of, not instead of, lifestyle. Whether lifestyle changes are enough on their own is a clinical judgment about an individual’s risk, not something a trial answers in general.

Does this series tell me what my targets should be?

No. StudyBackedHealth reports what the trials and guidelines found, including the specific targets those studies used, such as the systolic goals compared in SPRINT (SPRINT Research Group, NEJM, 2015). We do not translate those into a target for you or tell you what to take. Those decisions depend on your full medical picture and belong with your own clinician.